788 Results
Sort By:
Published on May 26, 2022
Elevation Oncology’s drug candidate seribantumab, currently being evaluated is a Phase II study, has received FDA Fast Track designation for tumor-agnostic treatment of advanced cancers harboring an NRG1 gene fusion. Seribantumab is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (HER3). HER3 is…
Published on April 27, 2022
Knowing whether chemotherapy has been successful in treating cancer is always critical, especially in the case of bladder cancer in which treatment failure often leads to radical cystectomy, or bladder removal surgery. Experienced physicians are able to make that determination. Now, a new machine learning tool has been created to…
Published on April 8, 2022
Sponsored content brought to you by NeoGenomics has added a new next-generation sequencing (NGS) assay to its lineup of oncology tests: RaDaR™. For insight into this new technology and how it’s set to transform care for cancer patients, Inside Precision Medicine turned to the Chief Medical Officer of Clinical Services…
Published on January 25, 2022
A study including data from more than 70,000 individuals shows that the chance of genetic variants labelled ‘pathogenic’ actually causing disease is low, although there is considerable variation between individual variants. Many people now undergo tests to look for genetic mutations that may increase a person’s risk for disease such…
Published on December 1, 2021
Growing evidence that precision medicine would save lives is what prompted each of the health systems covered in this article to adopt an aggressive program early. “This means improving care for our patients,” says Konstantinos N. Lazaridis, M.D., of Mayo Clinic. “It gives us more specific information about what causes…
Published on November 3, 2021
A monoclonal antibody (MAB) developed by scientists at University College London (UCL) allows more effective delivery of targeted cancer treatments in mice by improving tumor vascular function. The findings, published in the journal MED, are the first to demonstrate that inhibiting the activity of LRG1, a protein produced in many tumorous…
Published on October 20, 2021
New research led by investigators at MIT, has demonstrated that a patient’s own live tumor cells, damaged by chemotherapy, may also augment antitumor immunity. The results suggest these live cell adjuvants may enhance the effectiveness of immune checkpoint blockade (ICB) in tumors that wouldn’t normally respond to such treatment alone.…
Published on June 21, 2021
Epigenetic factors likely explain why not all individuals with type 1 diabetes genetic risk variants go on to develop the condition, according to researchers based at Huazhong University of Science and Technology. Type 1 diabetes is a heterogenous condition and is thought to have different causes in different people. Genetic…
Published on June 18, 2021
Studies in laboratory cell lines and in mouse tumor models show an antibiotic developed in the 1950s called novabiocin effectively targets and kills cancer cells with abnormal BRCA1 or BRCA2 genes, which normally help to repair damaged DNA. The research team, based at the Dana-Farber Cancer Institute, showed the drug…
Published on November 20, 2020
In the 1990s, Elissa Levin proposed a master’s thesis on using the Internet to extend the reach of genetic counselors. Quickly, her committee shut down that idea. In those “old days”—just a few decades ago—many genetic counselors believed that only face-to-face assessments could be useful. In the midst of the…
Published on April 27, 2020
Investigators at the German Cancer Research Center in Heidelberg (DKFZ) and the Mannheim Medical Faculty of the University of Heidelberg have released data on an antibody they created that blocks a receptor that stimulates the formation of new blood vessels in tumors and metastasis. Findings from the new stud—published recently…
Published on April 1, 2020
Thyroid dysfunction following cancer treatment with immune checkpoint inhibitors is more common than previously thought, according to research accepted for presentation at the Endocrine Society’s annual meeting (which was cancelled), and soon to be published in a special supplemental section of the Journal of the Endocrine Society. Cancer immunotherapy, particularly treatment…
Published on January 17, 2020
Nucleic acid developer and manufacturer Integrated DNA Technologies (IDT) announced this week it was expanding it global partnership with genomic and radiomic analysis company SOPHiA Genetics to bundle IDT’s kits and reagents with the SOPHiA analytic platform. “Our strong relationship with IDT has enabled us to further accelerate the democratization…
Published on January 16, 2020
As immune checkpoint inhibitor drugs have shown spectacular results in some patients, while other patients show little or no response, the race is on to develop biomarkers of immune activity that can help identify responders from non-responders. Now, a team of investigators at Johns Hopkins Kimmel Cancer Center, the Bloomberg-Kimmel Institute…
Published on December 31, 2019
A research team led by Hongzhe Sun from the Department of Chemistry at the University of Hong Kong (HKU), in collaboration with researchers including Junwen Wang from Mayo Clinic, Arizona, have used a deep learning approach to predict disease-associated mutations of the metal-binding sites in a protein. Understanding such mutations could…